Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Harvoni was produced by Bristol-Myers Squibb.

Samsung Bioepis wins CHMP nod for second Humira biosimilar

Samsung Bioepis wins CHMP nod for second Humira biosimilar Both were reviewed under the accelerated assessment protocol because despite the robust efficacy of current drugs such as Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira (ombitasvir/paritaprevir/ritonavir and

Two new hepatitis C therapies fast-tracked in Europe

Two new hepatitis C therapies fast-tracked in Europe Sofosbuvir and velpatasvir are the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa, as a successor to its massively successful Harvoni (sofosbuvir/ledipasvir) but with activity ... Analysts at Leerink have previously

The future of biotech

The future of biotech IMS data for 2015 highlighted that six out of ten of the world's best-selling medicines were biologics: $18bn for Harvoni, a new medicine; $15bn for Humira and $6bn for

Global drug spending will rise by a third to $1.5trn in 2021

Global drug spending will rise by a third to $1.5trn in 2021 The uptick stemmed from the launched of new drugs for hepatitis C such as Gilead's Sovaldi and Harvoni as well as new cancer medicines, but the impact of these will

Torrid times at Gilead lead to calls for a major M&A deal

Torrid times at Gilead lead to calls for a major M&A deal Sales of its hepatitis drugs Sovaldi, Harvoni and Epclusa were down $1.5bn in the same period of 2015 to $3.3bn, with overall revenues down almost 10% to $7.5bn

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics